Clinical trial
Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3)
NCT05293600 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treating Residual OSA With Endotype-directed Pharmacotherapy (Aim 3)
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 1, 2023
- Completion date
- October 30, 2026
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
obstructive sleep apnea